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Resistance to growth hormone (GH)-induced insulin-like
growth factor-1 (IGF-1) gene expression contributes to
uremic muscle wasting. Since exercise stimulates muscle
IGF-1 expression independent of GH, we tested whether
work overload (WO) could increase skeletal muscle IGF-1
expression in uremia and thus bypass the defective GH
action. Furthermore, to provide insight into the mechanism
of uremic wasting and the response to exercise we examined
myostatin expression. Unilateral plantaris muscle WO was
initiated in uremic and pairfed (PF) normal rats by ablation of
a gastrocnemius tendon and adjoining part of this muscle
with the contralateral plantaris as a control. Some rats were
GH treated for 7 days. WO led to similar gains in plantaris
weight in both groups and corrected the uremic muscle
atrophy. GH increased plantaris IGF-1 mRNA 4twofold in PF
rats but the response in uremia was severely attenuated. WO
increased the IGF-1 mRNA levels significantly in both uremic
and PF groups, albeit less brisk in uremia; however, after 7
days IGF-1 mRNA levels were elevated similarly, 42-fold, in
both groups. In the atrophied uremic plantaris muscle basal
myostatin mRNA levels were increased significantly and
normalized after an increase in WO suggesting a myostatin
role in the wasting process. In the hypertrophied uremic left
ventricle the basal myostatin mRNA levels were reduced and
likely favor the cardiac hypertrophy. Together the findings
provide insight into the mechanisms of skeletal muscle
wasting in uremia and the hypertrophic response to exercise,
and suggest that alterations in the balance between IGF-1
and myostatin play an important role in these processes.
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Muscle wasting is common in patients with advanced kidney
failure and if sustained this has an adverse effect on the
clinical course of the patient.1,2 Multiple factors contri-
bute to this wasting state including reduced protein–calorie
intake, acidosis, inflammation, diabetes and acquired
resistance to or deficiency of anabolic hormones such as
growth hormone (GH), insulin-like growth factor-1 (IGF-1),
insulin, and testosterone.3–6 Although little is known about
the role of myostatin in uremia,7 it is conceivable that this
negative regulator of muscle mass8 also contributes to uremic
muscle wasting. IGF-1 is of special interest as it plays
a central role in the control of muscle growth, repair and the
maintenance of muscle mass,9–11 and mediates most growth-
promoting actions of GH. Indeed, it is now established
that alterations in the GH–IGF-1 system especially resistance
to IGF-1 action12,13 and impaired IGF-1 production in
response to GH14–16 contribute to the wasted state in
uremia. Resistance to IGF-1 arises because of the accumula-
tion of high-affinity insulin-like binding proteins which trap
IGF-1 and reduce its bioavailability14 and also because of a
defect in IGF-1-mediated signaling.12 Impaired GH-mediated
IGF-1 production arises largely because of a signaling
defect.17,18
IGF-1 is produced in tissues throughout the body largely
under the influence of GH with the liver as the main source
of circulating hormone.19 In skeletal muscle IGF-1 produc-
tion is regulated by GH and by mechanical stimuli induced
by exercise in a GH-independent manner,20,21 and this likely
contributes to the beneficial effects of exercise on muscle
structure and function.10,22–24 Our prior studies in uremic
rats indicate that resistance to GH arises largely due to a
defect in GH-mediated Janus kinase 2-signal transducers and
activators of transcription 5 signal transduction,17,18,25 a
pathway essential for GH-stimulated IGF-1 expression.26
Reduced GH receptor expression,14 though not a universal
finding,17,18,25 may be another cause of GH resistance. In
humans with kidney failure, resistance to GH and IGF-1 not
only impairs maintenance of muscle bulk but also inhibits
linear growth.3,14,16 Administration of GH in relatively high
doses produces an increase in linear growth and muscle mass
in children27 and a positive anabolic response in adults with
advanced renal failure.3,28
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In view of the resistance to GH-stimulated IGF-1
expression that develops in uremia,17,18,25 we set out to
determine, whether we could bypass this defect by activating
a GH-independent stimulus of local IGF-1 expression,
namely increased muscle work load,20,21 and thus stimulate
muscle IGF-1 expression and hypertrophy. In addition, to
provide further insight into the mechanism of muscle
wasting and the response to resistance exercise in uremia,
we examined the expression of myostatin, a major negative
regulator of muscle mass that limits muscle fiber growth.8,29
Myostatin also known as growth and differentiation factor-8,
is a member of the transforming growth factor-b super family
that is expressed in skeletal and cardiac muscle.8,29,30
Spontaneous mutations of the myostatin gene lead to an
increase in muscle mass as recently reported in a child,31 and
accounts for the enormous muscular hypertrophy present in
Belgium blue cattle.29 In contrast when active myostatin is
present in excess as described in acquired immunodeficiency
syndrome, following glucocorticoid therapy or muscle
unloading, muscle mass and function is reduced.8,32
Resistance exercise usually depresses myostatin expres-
sion,33–36 but this is not a uniform finding.37
To achieve our goals we studied rats with surgically
induced chronic renal failure (CRF) and unilateral work
overload (WO) of the plantaris muscle induced by excision of
one gastrocnemius tendon and adjoining part of the muscle.
In this model of resistance exercise we show that despite the
presence of GH resistance, sustained WO can effectively
stimulate IGF-1 expression and muscle hypertrophy. Further-
more, we show that skeletal muscle myostatin expression is
increased in uremia and falls following an increase in work
load.
RESULTS
Serum biochemistry and anthropometrics
After 21 days of CRF serum creatinine and urea nitrogen
levels were increased significantly compared to pairfed (PF)
sham-nephrectomized control values (Table 1). In contrast,
serum total CO2 levels in CRF rats were similar to the control
values. Body weight and plantaris muscle weight despite pair
feeding, were significantly lower in uremic rats while left
ventricular weight was increased.
Rats with CRF are resistant to GH induced body weight gain
and stimulation of IGF-1 gene expression
Resistance to GH therapy was evident in CRF rats as
previously described; treatment with GH for 7 days failed to
cause an increase in body weight gain compared to vehicle
(V)-treated CRF rats (37.272.1 vs 3674.7 g/7 days,
respectively; Figure 1a). In contrast body weight increased
significantly in PF controls treated with GH compared to
V-treated controls (65.573.3 vs 40.473.5 g; Po0.01). GH
had no effect on serum biochemistry in either group (data
not show). In respect to IGF-1 gene expression, resistance to
GH was also evident in the CRF group. As shown in Figure
1b, which depicts the findings in the control non-overloaded
plantaris muscle, basal IGF-1 mRNA levels in the PF and CRF
rats did not differ significantly even though the average levels
were lower in the CRF group (100716 vs 73714 relative
arbitrary units). Following GH treatment IGF-1 mRNA levels
increased in both groups, but the response was significantly
attenuated in the CRF group (P40.01). The relative IGF-1
mRNA levels rose to 137725 arbitrary units in the CRF
group compared to 223731 arbitrary units in the PF rats.
WO induces muscle hypertrophy in CRF
WO of the plantaris muscle induced by unilateral ablation of
the gastrocnemius tendon and distal muscle was followed by
similar increases in plantaris muscle weight in both CRF and
PF rats even though the control CRF muscle weights were
lower (Figure 2). After 2 days of overload the plantaris
muscle weight in the PF and CRF rats increased above the
contralateral control values by 2278 and1976 mg, respec-
tively, and after 7 days by 86716 and 100712 mg,
respectively. Thus, while the total weight of the overloaded
CRF muscle remained below that of the overloaded muscle of
Table 1 | Biochemical and anthropometric characteristics
of CRF and pairfed sham-ephrectomized rats
PF CRF
Number of rats 11 14
Serum creatinine (mg/dl) 0.3570.03 1.4870.13**
Serum urea nitrogen (mg/dl) 1771 8679**
Serum bicarbonate (mmol/l) 2770.86 2570.65
Body weight (g) 23774 20676**
Control plantaris weight (mg) 25476 20278**
LV weight (g) 0.5470.02 0.6470.01**
LV/BW (%) 0.2270.01 0.3170.01**
BW, body weight; CRF, chronic renal failure; LV, left ventricle; PF, pairfed.
**Po 0.01.
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Figure 1 | Growth hormone stimulated body weight gain and
IGF-1 mRNA expression is severely impaired in CRF. (a) Body
weight. (b) Control plantaris muscle IGF-1 mRNA levels. Rats with CRF
or PF rats were treated with bovine growth hormone (GH) or vehicle
(V) for 7 days and then killed. IGF-1 mRNA levels in the plantaris
muscle from control intact non-loaded limbs from CRF and sham
nephrectomized. PF rats were measured by quantitative real-time
PCR and corrected for the internal housekeeping gene L7 which
is unaffected by uremia or GH. Results, mean7s.e.m. of 11–14 rats/
group, are expressed relative to the PF V-treated control group and
assigned a mean value of 100. **Po0.01 vs V treated.
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the PF rats, the CRF values reached levels that did not differ
significantly from that of the control PF values. In other
words WO appears to correct uremic muscle atrophy.
WO stimulates IGF-1 gene expression in skeletal muscle
of CRF rats
WO of the plantaris muscle (Figure 3) induced a significant
increase in local IGF-1 mRNA levels in both the CRF and PF
rats compared to the contralateral non-loaded control values
(Po0.01). After 2 days of WO the relative IGF-1 mRNA level
increased significantly in both groups of rats though to a
lesser level in the CRF rats; relative IGF-1 mRNA levels
increased to 320783 in the PF group (P40.01) and 180714
arbitrary units, in the CRF group (Po0.05). After 7 days of
WO, plantaris muscle IGF-1 mRNA levels increased further
in the CRF group and reached a level similar to that in the PF
group (266744 vs 220740 arbitrary units, respectively).
Thus, exercise is an effective stimulus of IGF-1 gene
expression in uremia, despite resistance to GH-induced IGF-
1 expression.
Plantaris muscle myostatin mRNA levels are elevated in CRF
and are depressed following WO
Figure 4 illustrates the changes in myostatin mRNA that
occur in uremia. Of note there was a 42-fold increase in the
myostatin mRNA levels of the control plantaris muscle of the
uremic rats compared to the values in the PF rats (Po0.01).
WO for 2 or 7 days depressed the elevated myostatin mRNA
levels significantly in the CRF rats (Po0.01), and caused a
small but significant decrease in the PF group after 7 days.
Taken together this suggests that in uremia over expression of
myostatin may contribute to the development of muscle
wasting and that exercise induced hypertrophy may arise in
part through the suppression of myostatin gene expression.
Cardiac muscle myostatin expression is depressed in the
hypertrophied left ventricle of uremic rats
Following 21 days of CRF there was a significant increase in
left ventricular weight and left ventricular weight corrected
for body weight compared to the PF values (Table 1 and
Figure 5, Po0.01). This presumably reflects a response to
increased work induced by hypertension and fluid overload
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Figure 2 | WO induces a similar increase in skeletal muscle weight
in CRF and PF rats even though the weight of control (CON)
unloaded muscle is lower in CRF. Rats were studied 2 or 7 days
after an unilateral increase in work load induced by excision of one
distal gastrocnemius tendon and part of the muscle. Results are
mean7s.e.m. from 5 to 8 rats/group. *Po0.05, **Po0.01.
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Figure 3 | WO increases plantaris muscle IGF-1 mRNA levels in
CRF and PF rats. Plantaris muscles from both limbs were collected 2
or 7 days after unilateral excision of a gastrocnemius tendon and part
of the muscle. IGF-1 mRNA levels were measured in the WO and
contralateral control (CON) plantaris muscle by real-time PCR and
corrected for the internal housekeeping gene L7 which is unaffected
by WO. The results, mean 7 s.e.m. from 5 to 8 muscles/group, are
expressed relative to the values obtained from the non-loaded
control plantaris muscle of the PF vehicle (V)-treated group, assigned
a mean value of 100. *Po0.05. **Po0.01.
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Figure 4 | Plantaris muscle myostatin mRNA levels are increased
in CRF and fall when work load is increased for 2 or 7 days.
Results are from the same animals as in Figure 3. Myostatin mRNA
levels were measured by real-time PCR and corrected for the internal
housekeeping gene L7. *Po0.05, **Po0.01.
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Figure 5 | Cardiac muscle myostatin (a) mRNA levels are
depressed in the hypertophied left ventricle of (b) CRF rats.
Myostatin mRNA levels were measured by real-time PCR and
corrected for the internal housekeeping gene L7. Results are from the
rats undergoing tendon ablation 2 days before killing. *Po0.05.
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observed in rats following a 5/6 nephrectomy.38 In the uremic
rats as shown in Figure 5, the relative myostatin mRNA level
in the left ventricle were significantly depressed to a value that
was two thirds of the PF control values (Po0.05). We suggest
that the depression of cardiac myostatin expression may well
play a role in the hypertrophy of the left ventricle. Inte-
restingly in contrast to the reduction in myostatin expression,
relative IGF-1 mRNA levels in the uremic myocardium did
not differ from the PF values (8874 vs 10079 arbitrary
units), a finding consistent with our previous report.25
DISCUSSION
In this study of rats with CRF and muscle wasting we set out
to test the thesis that expression of IGF-1 can be increased
through activation of a GH-independent mechanical stimu-
lus, namely increased muscle work load,20 despite the
presence of resistance to GH induced increases in IGF-1
mRNA levels which arises largely due to a defect in GH-
mediated Janus kinase 2-signal transducers and activators of
transcription 5 signal transduction.17,18,25 In addition, in
order to provide further insight into the mechanism of
uremic wasting and the response to exercise, we examined the
expression of myostatin. As before17,18,25 we found that the
CRF rats were relatively resistant to the growth-promoting
action of GH and to GH stimulation of IGF-1 mRNA
expression. In contrast, unilateral plantaris muscle WO
induced by excision of a gastrocnemius tendon and portion
of the muscle, caused a significant albeit less brisk increase in
local IGF-1 mRNA levels in the CRF rats that reached levels
similar to that achieved in the PF sham-nephrectomized rats.
The less brisk IGF-1 response in the CRF rats could
conceivably arise because of reduced physical activity in the
uremic state, though in the same rats WO produced an early
and effective decrease in elevated myostatin levels and Adams
et al.38 reported that voluntary activity was not impaired in
5/6 nephrectomized rats. In both CRF and PF rats the work
induced increase in IGF-1 mRNA levels was accompanied by
a significant increase in muscle weight and in the CRF rats
this corrected the uremic muscle atrophy. Since IGF-1 is
known to cause muscle hypertrophy,9,39,40 these findings are
consistent with a role for local IGF-1 in inducing the
observed increase in muscle mass.
Interesting changes in myostatin expression were also
noted. In the CRF rats the myostatin mRNA levels in the
atrophied non-overloaded plantaris muscle were more than
twofold higher than in the corresponding plantaris muscle in
PF rats. Furthermore, following an increase in work load the
myostatin mRNA levels fell in the CRF rats to values that
were similar or on average even lower than the basal levels in
PF rats. The situation in the heart of CRF rats differed. In
contrast to skeletal muscle atrophy with elevated myostatin
mRNA levels, the left ventricular muscle was hypertrophied
and the myostatin levels were significantly reduced compared
to the PF group. We suggest that this may reflect a response
to an increase in cardiac muscle work induced by hyper-
tension and fluid retention in the uremic state.38
Circulating IGF-1 is largely derived from hepatic secretion
and like IGF-1 produced in other tissues including muscle, is
regulated by GH via the Janus kinase 2-signal transducers and
activators of transcription 5 signal transduction pathway.19
Skeletal muscle IGF-1 is also produced in response to
mechanical stimuli such as exercise in a GH-independent
manner20,21 and this local IGF-1 plays an important role in
muscle growth and repair.19,40,41 When exercise is prolonged
IGF-1 released from muscle contributes to the circulating
pool,42 though circulating IGF-1 appears to be less important
than local IGF-1 in promoting muscle growth.43 The
structure of the mature IGF-1 peptide is relatively simple,
but its gene structure and pattern of expression is complex
and this results in the formation of multiple transcripts.19,40
In the present study, we measured the total mRNA level of all
IGF-1 transcripts and following WO the level increased in
both the CRF and PF groups despite a lack of response to
recombinant GH.
The mechanisms whereby mechanical stimuli activated by
skeletal muscle work induce hypertrophy are poorly under-
stood.44 One key mechanism is the induction of IGF-1 gene
expression with increased IGF-1 peptide production.9,10 This
local peptide promotes cell proliferation and differentiation,
stimulates protein synthesis and inhibits proteolysis and does
so largely through activation of the phosphatidylinositol 30
kinase/Akt-signaling pathway.5,10,11,44 Interestingly down-
stream components of this same pathway are also activated
by mechanical stimuli independent of IGF-1 and together
with IGF-1 promote an increase in muscle mass.10,44 Our
present findings in a rat model of resistance exercise is
consistent with human studies showing that resistance
exercise is an effective means of inducing skeletal muscle
hypertrophy in kidney failure23,24 and is compatible with a
role for local IGF-1, independent of GH, in this process.
It has been reported that serum IGF-I levels are normal or
even elevated in adults receiving maintenance dialysis7,45 but
are reduced in those that are severely malnourished.15
Children with CRF have normal or low normal IGF-1 levels
and there is evidence suggesting that IGF-1 secretion is
attenuated despite normal or elevated GH levels, findings
consistent with GH resistance.14 In adults with end-stage
renal disease skeletal muscle IGF-1 peptide levels have been
reported to be low in subjects with muscle wasting45 and
increased in relatively well-nourished end-stage renal disease
subjects.7 However, as the expression of the major IGF-1
mRNA transcript, IGF-1Ea, was significantly depressed in the
latter study, the authors suggested that the increase in IGF-1
peptide noted may reflect trapping by local IGF binding
proteins.7 In uremic rats IGF-I mRNA levels may be reduced
in liver, muscle, and long bone growth plate,14 and to a large
extent this may reflect reduced food intake.15
Myostatin is another major regulator of skeletal muscle
mass.8,29 This negative regulator is expressed in skeletal and
cardiac muscle and impairs skeletal muscle growth by
inhibiting myoblast proliferation and differentiation and
satellite cell activation.8 Overexpression of myostatin as a
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cause of muscle atrophy has been implicated in several
wasting states.8,29 In contrast, myostatin gene mutations can
lead to a remarkable increase in muscle mass as described in
cattle and in a young child29,31 and experimental inhibition
of myostatin action is under study as a therapeutic for
muscle-wasting disorders.46 Exercise in the form of endur-
ance or resistance training can suppress myostatin expression
and induce muscle hypertrophy.7,29,36,47 In a study of
sedentary well-nourished maintenance hemodialysis subjects,
Wang et al.7 noted that skeletal muscle myostatin mRNA
levels were similar to normal control subject values and a
preliminary report22 indicates that myostatin mRNA fall
following prolonged endurance exercise training. In the
present study of rats with CRF and skeletal muscle atrophy
myostatin mRNA levels were more than two fold the values in
normal PF rat muscle. However following an increase in work
load, the elevated myostatin mRNA levels fell significantly
and reached values that did not differ significantly from PF
normal control values. This response was associated with an
increase in muscle weight. Accordingly it appears that the
work load induced fall in myostatin together with the
increase in IGF-1 expression likely contribute to the increase
in muscle mass. The difference in the basal myostatin mRNA
levels noted in the present study in muscle wasted CRF rats
and that of Wang et al.7 in humans, may reflect the fact that
the hemodialysis subjects were well nourished and had no
clinical evidence of muscle wasting. It is also possible that
there are species differences.
In contrast to the increase in skeletal muscle myostatin
mRNA levels present in the atrophied skeletal muscle of
uremic rats, the levels were reduced significantly in the
hypertrophied left ventricle of these same rats. We suggest
that this reduction may reflect the response to a prolonged
increase in left ventricular work load caused by hypertension
and fluid retention in CRF38 and may conceivably contribute
to the development of left ventricular hypertrophy.48 These
findings differ from that observed in other conditions that
cause cardiac hypertrophy. Cook et al.49 reported that
myostatin is upregulated in the hypertrophied hearts of
transgenic mice with cardiac-specific expression of activated
Akt, while Shyu et al.30 noted that after the creation of an
aorta–caval shunt in rats, there was an early increase in
cardiac myostatin peptide levels that returned to baseline
levels after 7 days. Both authors suggested that the myostatin
increase may reflect a negative feedback response to prevent
excessive cardiac hypertrophy. Studying cultured cardiomyo-
cytes Shyu et al.30 also showed that cyclic stretch stimulates
an increase in myostatin mRNA expression that returned to
baseline after 48 h. Thus, the difference in our findings in rats
after 21 days of CRF and that of Shyu et al.30 may reflect
temporal changes in the expression of myostatin in response
to mechanical stimuli. It is also possible that the increase in
cardiac myostatin in CRF occurs through mechanisms
peculiar to the uremic state. Further study to clarify the role
of myostatin and its regulation in different diseases that affect
the heart is required.
In conclusion, we have shown that an increase in skeletal
muscle work load is an effective means of stimulating local
IGF-1 mRNA expression in the uremic state despite severe
resistance to GH-stimulated IGF-1 expression. Furthermore,
the increase in work load leads to muscle hypertrophy and
taken together this is consistent with the anabolic action of
local IGF-1. We also found significant changes in the
expression of myostatin. Myostatin mRNA levels were
elevated in the atrophied skeletal muscle of the uremic rats
suggesting a role in the wasting process and following an
increase in muscle work load these abnormalities were
corrected. Taken together these findings add to our under-
standing of the mechanisms of uremic skeletal muscle
wasting and the hypertrophic response to exercise, and
appears to be consistent with a change in the balance between
local IGF-1 and myostatin expression. Finally, in contrast to
the high myostatin mRNA levels present in the atrophied
skeletal muscle of uremic rats, the levels were low in the
hypertrophied left ventricles. Overall these findings are
consistent with a role for myostatin in the pathogenesis of
skeletal muscle wasting and left ventricular hypertrophy.
MATERIALS AND METHODS
Experimental animals and protocols
Male Sprague–Dawley rats weighing B125 g were entered into the
study. CRF was created by a two-step 5/6 nephrectomy procedure
with ketamine (80 mg/kg) and xylazine (10 mg/kg) anesthesia as
before.17 Sham nephrectomy operations were performed on other
animals that were PF with the CRF rats to control for the impact of
nutrition on IGF-1 expression.15 After 14 days half the CRF and PF
sham-nephrectomized rats underwent a surgical procedure to
produce unilateral WO of the plantaris muscle, a model of resistance
exercise,20 with the contralateral plantaris muscle of the same animal
serving as a control. The remaining animals underwent the same
procedure after 19 days of CRF and all animals were killed after 21
days of CRF. In brief, under ketamine and xylazine anesthesia the
distal gastrocnemius tendon of one leg was exposed, the tendon and
lower quarter of the muscle was excised and then the skin incision
closed with a clip and the rats were allowed to recover from
anesthesia. No surgery was performed on the contralateral limb
which served as a paired control; in pilot studies we found that skin
incision and tendon exposure alone had no impact on plantaris
muscle IGF-1 gene expression. The following groups of 5–10 rats
were studied. PF and CRF groups with unilateral WO for 2 days. PF
and CRF groups with unilateral WO for 7 days and treated either
with V or recombinant bovine GH (gift from Monsanto Corp., St
Louis, MO, USA) 5 mg/kg s.c. twice a day. On the last day of the 7
day period, rats received GH or V 5 h apart and were killed 1 h after
the last injection to measure GH-stimulated IGF-1 expression.
Plantaris muscle was excised, weighed, and stored at 801C. Serum
was collected and creatinine and CO2 levels were measured with a
Beckman LX 20 Analyzer (Beckman Coulter Inc., Fullerton, CA,
USA).
Real-time quantitative reverse transcriptase-polymerase
chain reaction assay
Real-time quantitative reverse transcriptase-polymerase chain reac-
tion (PCR) with SYBR green dye as the detection agent was
performed with the ABI Prism 7900 Sequence Detection System
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(Applied Biosystems, Foster City, CA, USA) using the manufactures
protocol (Perkin-Elmer Applied Biosystems (1997) User Bulletin 2
updated 2001: ABI Prism 7700 Sequence Detection System, Relative
Quantitation of Gene Expression, Applied Biosystems, Foster City,
CA, USA). Primers for the quantitation of the IGF-1, myostatin and
internal control genes, ribosomal 18S and L7 (Table 2), were
designed using the primer design software Primer Express (Applied
Biosystems) and from published sequences and were synthesized by
Qiagen Inc. (Alameda, CA, USA). For IGF-1 detection, primers and
probes were designed to amplify and detect all splice variants of the
IGF-1 mRNA. Total RNA was extracted from plantaris muscle and
used for cDNA synthesis by reverse transcription (Applied
Biosystems, Foster City, CA, USA) and the cDNA samples were
then subjected to PCR analysis. The results were quantified using the
relative standard curve method as described by the supplier. An
internal control gene standard curve was also generated and the
target gene is normalized for this endogenous control. Each sample
was analyzed in triplicate in individual assays performed on two or
more occasions.
Data analysis and statistics
Specific mRNAs were normalized for the internal control gene and
are expressed as transcript/housekeeping gene ratios. The control
vehicle treated PF group mean was given a value of 100, and
individual values are expressed relative to this value. Data are given
as mean7s.e.m. Two-tailed unpaired Student’s t-tests were applied
for comparison of two normally distributed groups, where
appropriate paired t-tests were applied to compare left and right
planatris muscles from the same animal; comparisons between more
than two normally distributed groups were made by one-way
analysis of variance followed by pairwise multiple comparison with
the Holms t-test.50 A P-value o0.05 was considered significant.
ACKNOWLEDGMENTS
This study was supported by Merit Review Grant from the Research
Service of the Department Veterans Affair and a Grant-in-Aid from the
American Heart Association.
REFERENCES
1. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive
value of commonly measured variables and an evaluation of death rate
differences between facilities. Am J Kidney Dis 1990; 15: 458–482.
2. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N et al. Revisiting mortality
predictability of serum albumin in the dialysis population: time
dependency, longitudinal changes and population-attributable fraction.
Nephrol Dial Transplant 2005; 20: 1880–1888.
3. Rabkin R. Therapeutic use of growth factors in renal disease. In: Kopple
JD, Massry SG (eds). Kopple and Massry’s Nutritional Management of Renal
Disease. Lipincott and Williams & Wilkens: Philadelphia, 2003, pp 581–592.
4. Kaysen GA. Inflammation: cause of vascular disease and malnutrition in
dialysis patients. Semin Nephrol 2004; 24: 431–436.
5. Du J, Hu Z, Mitch WE. Molecular mechanisms activating muscle protein
degradation in chronic kidney disease and other catabolic conditions. Eur
J Clin Invest 2005; 35: 157–163.
6. Johansen KL. Treatment of hypogonadism in men with chronic kidney
disease. Adv Chronic Kidney Dis 2004; 11: 348–356.
7. Wang H, Casaburi R, Taylor WE et al. Skeletal muscle mRNA for IGF-IEa,
IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis
patients. Kidney Int 2005; 68: 352–361.
8. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol
2004; 288: E1110–E1119.
9. Goldspink G. Impairment of IGF-I gene splicing and MGF expression
associated with muscle wasting. Int J Biochem Cell Biol 2005; 37:
2012–2022.
10. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways.
Int J Biochem Cell Biol 2005; 37: 1974–1984.
11. Heszele MF, Price SR. Insulin-like growth factor I: the yin and yang of
muscle atrophy. Endocrinology 2004; 145: 4803–4805.
12. Ding H, Gao XL, Hirschberg R et al. Impaired actions of insulin-like growth
factor 1 on protein synthesis and degradation in skeletal muscle of rats
with chronic renal failure. Evidence for a postreceptor defect. J clin Invest
1996; 97: 1064–1075.
13. Fouque D, Peng SC, Kopple JD. Impaired metabolic response to
recombinant insulin-like growth factor-1 in dialysis patients. Kidney Int
1995; 47: 876–883.
14. To¨nshoff B, Kiepe D, Ciarmatori S. Growth hormone/insulin-like growth
factor system in children with chronic renal failure. Pediatr Nephrol 2005;
20: 279–289.
15. Rabkin R. The kidney and the insulin-like growth factor system in health
and disease. In: Houston M, Holly J, Feldman E (eds). IGF and Nutrition in
Health and Disease. Humana Press: Totawa NJ, 2004, pp 227–250.
16. Kaskel F. Chronic renal disease: a growing problem. Kidney Int 2003; 64:
1141–1151.
17. Schaefer F, Chen Y, Tsao T et al. Impaired JAK-STAT signal transduction
contributes to growth hormone resistance in chronic uremia. J Clin Invest
2001; 108: 467–475.
18. Sun DF, Zheng Z, Tummala P et al. Chronic uremia attenuates growth
hormone-induced signal transduction in skeletal muscle. J Am Soc
Nephrol 2004; 15: 2630–2636.
19. Woelfle J, Chia DJ, Massart-Schlesinger MB et al. Molecular physiology,
pathology, and regulation of the growth hormone/insulin-like growth
factor-I system. Pediatr Nephrol 2005; 20: 295–302.
20. DeVol DL, Rotwein P, Sadow JL et al. Activation of insulin-like growth
factor gene expression during work-induced skeletal muscle growth. Am
J Physiol 1990; 259: E89–E95.
21. Zanconato S, Moromisato DY, Moromisato MY et al. Effect of training and
growth hormone suppression on insulin-like growth factor I mRNA in
young rats. J Appl Physiol 1994; 76: 2204–2209.
22. Kopple JD, Storer T, Casburi R. Impaired exercise capacity and
exercise training in maintenance hemodialysis patients. J Ren Nutr 2005;
15: 44–48.
23. Castaneda C, Gordon PL, Parker RC et al. Resistance training to reduce the
malnutrition-inflammation complex syndrome of chronic kidney disease.
Am J Kidney Dis 2004; 43: 607–616.
24. Mercer TH, Koufaki P, Naish PF. Nutritional status, functional capacity and
exercise rehabilitation in end-stage renal disease. Clin Nephrol 2004;
61(Suppl 1): S54–S59.
25. Zheng Z, Sun DF, Tummala P, Rabkin R. Cardiac resistance to growth
hormone in uremia. Kidney Int 2005; 67: 858–866.
26. Woelfle J, Rotwein P. In vivo regulation of growth hormone-stimulated
gene transcription by STAT5b. Am J Physiol Endocrinol Metab 2004; 286:
E393–E401.
27. Fine RN, Kohaut E, Brown D et al. Long-term treatment of growth
retarded children with chronic renal insufficiency, with recombinant
human growth hormone. Kidney Int 1996; 49: 781–785.
28. Kopple JD, Brunori G, Leiserowitz M, Fouque D. Growth hormone induces
anabolism in malnourished maintenance haemodialysis patients. Nephrol
Dial Transplant 2005; 20: 952–958.
Table 2 | Primer sequences for quantitative real-time PCR analysis
Forward (50–30) Reverse (50–30)
18S GGGAATTCCTGCCAGTAGCATATGCTTG GGAAGCTTAGAGGAGCGAGCGACCAAAG
L-7 GAAAGGCAAGGAGGAAGCTCATT AATCTCAGTGCGGTACATCGCCT
IGF-1 CCGCTGCAAGCCTACAAAGT TGAGTCTTGGGCATGTCAGTGT
Myostatin CAGGACCAGGAGAAGATGGGCT CGATTCCGTGGAGTGAACATCAC
IGF-1: insulin-like growth factor-1; PCR: polymerase chain reaction.
458 Kidney International (2006) 70, 453–459
o r i g i n a l a r t i c l e DF Sun et al.: Muscle IGF-1 and myostatin expression in uremia
29. Matsakas A, Diel P. The growth factor myostatin, a key regulator in
skeletal muscle growth and homeostasis. Int J Sports Med 2005; 26: 83–89.
30. Shyu K, Ko WH, Yang WS et al. Insulin-like growth factor-1 mediates
stretch-induced upregulation of myostatin expression in neonatal rat
cardiomyocytes. Cardiovasc Res 2005; 68: 405–414.
31. Schuelke M, Wagner KR, Stolz LE et al. Myostatin mutation associated
with gross muscle hypertrophy in a child. N Engl J Med 2004; 350:
2682–2688.
32. McNally E, Elizabeth M. Powerful genes – myostatin regulation of human
muscle mass. N Engl J Med 2004; 350: 2642–2644.
33. Kim JS, Cross JM, Bamman MM. impact of resistance loading on
myostatin expression and cell cycle regulation in young and older men
and women. Am J Physiol Endocrinol Metab 2005; 20: 61–86.
34. Kawada S, Tachi C, Ishii N. Content and localization of myostatin in mouse
skeletal muscles during aging, mechanical unloading and reloading.
J Muscle Res Cell Motil 2001; 22: 627–633.
35. Matsakas A, Friedel A, Hertrampf T, Diel P. Short-term endurance training
results in a muscle-specific decrease of myostatin mRNA content in the
rat. Acta Physiol Scand 2005; 183: 299–307.
36. Roth SM, Martel GF, Ferrell RE et al. Myostatin gene expression
is reduced in humans with heavy-resistance strength training: a brief
communication. Exp Biol Med (Maywood) 2003; 228: 706–709.
37. Willoughby D, Darryn S. Effects of heavy resistance training on myostatin
mRNA and protein expression. Med Sci Sports Exerc 2004; 36: 574–582.
38. Adams GR, Zhan CD, Haddad F, Vaziri ND. Voluntary exercise during
chronic renal failure in rats. Med Sci Sports Exerc 2005; 37: 557–562.
39. Rotwein P. Insulin-like growth factor action and skeletal muscle growth,
an in vivo perspective. Growth Horm IGF Res 2003; 13: 303–305.
40. Winn N, Paul A, Musaro A, Rosenthal N. Insulin-like growth factor isoforms
in skeletal muscle aging, regeneration, and disease. Cold Spring Harb
Symp Quant Biol 2002; 67: 507–518.
41. Rennie MJ, Wackerhage H, Spangenburg EE, Booth FW. Control
of the size of the human muscle mass. Annu Rev Physiol 2004; 66:
799–828.
42. Berg U, Bang P. Exercise and circulating insulin-like growth factor I. Horm
Res 2004; 62(Suppl 1): 50–58.
43. Yakar S, Liu JL, Stannard B et al. Normal growth and development in the
absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA
1999; 96: 7324–7329.
44. Tidball JG. Mechanical signal transduction in skeletal muscle growth and
adaptation. J Appl Physiol 2005; 98: 1900–1908.
45. Macdonald JH, Phanish MK, Marcora SM et al. Muscle insulin-like growth
factor status, body composition, and functional capacity in hemodialysis
patients. J Ren Nutr 2004; 14: 248–252.
46. Roth SM, Walsh S. Myostatin: a therapeutic target for skeletal muscle
wasting. Curr Opin Clin Nutr Metab Care 2004; 7: 259–263.
47. Carlson CJ, Booth FW, Gordon SE. Skeletal muscle myostatin mRNA
expression is fiber-type specific and increases during hindlimb unloading.
Am J Physiol 1999; 277: R601–R606.
48. Gaussin V, Depre C. Myostatin, the cardiac chalone of insulin-like growth
factor-1. Cardiovasc Res 2005; 68: 347–349.
49. Cook SA, Matsui T, Li L, Rosenzweig A. Transcriptional effects
of chronic Akt activation in the heart. J Biol Chem 2002; 277:
22528–22533.
50. Glantz S. Primer of Biostatistics, 5th edn. McGraw-Hill: New York, 2002 pp
92–103.
Kidney International (2006) 70, 453–459 459
DF Sun et al.: Muscle IGF-1 and myostatin expression in uremia o r i g i n a l a r t i c l e
